The Medicure Inc (MPH) Releases Quarterly Earnings Results, Misses Expectations By $0.37 EPS

The Medicure Inc (MPH) Releases Quarterly  Earnings Results, Misses Expectations By $0.37 EPS

About Medicure Medicure Inc (Medicure) is a pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. The Company operates in the biopharmaceutical industry segment. The Company’s primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc and distributed in the United States and its territories through the Company’s United States subsidiary, Medicure Pharma, Inc AGGRASTAT, a glycoprotein IIb/IIIa inhibitor (GPI), is used for the treatment of acute coronary syndrome (ACS).new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “TSXV:MPH”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for Medicure Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Medicure Inc and related companies with our FREE daily email newsletter.

Related posts

Leave a Comment